» Articles » PMID: 18940189

Neuroprotective Effect of Resveratrol on 6-OHDA-induced Parkinson's Disease in Rats

Overview
Journal Eur J Pharmacol
Specialty Pharmacology
Date 2008 Oct 23
PMID 18940189
Citations 134
Authors
Affiliations
Soon will be listed here.
Abstract

The present study was undertaken to investigate the neuroprotective effects of resveratrol on 6-hydroxydopamine (6-OHDA)-induced Parkinson's disease in rats. 6-OHDA-induced Parkinson's disease rat model involves chronic inflammation, mitochondrial dysfunction, and oxidative stress, and the loss of the dopaminergic neurons in the substantia nigra is the predominant lesion. Resveratrol has been shown to have anti-inflammatory actions, and thus was tested for its beneficial effects using 6-OHDA-induced Parkinson's disease rat model. Adult Sprague-Dawley (SD) rats were unilaterally injected with 6-OHDA (5 microg/2 microl) into the right striatum, and the striatum damage was assessed by rotational test, ultrahistopathology, and molecular alterations. Resveratrol (10, 20 and 40 mg/kg) was then given orally to Parkinson's disease rats, daily for 10 weeks to examine the protective effects. Rotational test (turns of rats) showed that resveratrol significantly attenuated apomorphine-induced turns of rats in 6-OHDA-injuried Parkinson's disease rat model as early as two weeks of administration. Ultrastructural analysis showed that resveratrol alleviated 6-OHDA-induced chromatin condensation, mitochondrial tumefaction and vacuolization of dopaminergic neurons in rat substantia nigra. Furthermore, resveratrol treatment also significantly decreased the levels of COX-2 and TNF-alpha mRNA in the substantia nigra as detected by real-time RT-PCR. COX-2 protein expression in the substantia nigra was also decreased as evidenced by Western blotting. These results demonstrate that resveratrol exerts a neuroprotective effect on 6-OHDA-induced Parkinson's disease rat model, and this protection is related to the reduced inflammatory reaction.

Citing Articles

Mechanism and Clinical Application Prospects of Mitochondrial DNA Single Nucleotide Polymorphism in Neurodegenerative Diseases.

Xu M, Li T, Liu X, Islam B, Xiang Y, Zou X Neurochem Res. 2024; 50(1):61.

PMID: 39673588 DOI: 10.1007/s11064-024-04311-9.


Resveratrol: A Natural Compound Targeting the PI3K/Akt/mTOR Pathway in Neurological Diseases.

Utpal B, Mokhfi F, Zehravi M, Sweilam S, Gupta J, Kareemulla S Mol Neurobiol. 2024; .

PMID: 39578340 DOI: 10.1007/s12035-024-04608-4.


The potential of natural products to inhibit abnormal aggregation of α-Synuclein in the treatment of Parkinson's disease.

Yang K, Lv Z, Zhao W, Lai G, Zheng C, Qi F Front Pharmacol. 2024; 15:1468850.

PMID: 39508052 PMC: 11537895. DOI: 10.3389/fphar.2024.1468850.


Development, Statistical Optimization, and Characterization of Resveratrol-Containing Solid Lipid Nanoparticles (SLNs) and Determination of the Efficacy in Reducing Neurodegenerative Symptoms Related to Alzheimer's Disease: In Vitro and In Vivo Study.

Khishvand M, Yeganeh E, Zarei M, Soleimani M, Mohammadi M, Mahjub R Biomed Res Int. 2024; 2024:7877265.

PMID: 39376256 PMC: 11458308. DOI: 10.1155/2024/7877265.


Neuroprotective effects of L-Dopa-modified zinc oxide nanoparticles on the rat model of 6-OHDA-ınduced Parkinson's disease.

Yeni Y, Genc S, Sait Ertugrul M, Nadaroglu H, Gezer A, Mendil A Sci Rep. 2024; 14(1):19077.

PMID: 39154054 PMC: 11330516. DOI: 10.1038/s41598-024-69324-4.